Tirzepatide and the risk of atherosclerotic cardiovascular events: population based cohort study

More on Type 2 diabetes

• Lancet·4 Oct 2026

  Orforglipron matches insulin glargine on cardiovascular safety

• Cardiology and Therapy·4 Oct 2026

  Low-carb telemedicine links to fewer cardiovascular events

  

• Diabetes & Vascular Disease Research·4 Oct 2026

  SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs

• American Journal of Preventive Cardiology·4 Oct 2026

  Most US adults meeting PREVENT risk thresholds lack lipid therapy